A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer

94Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

PURPOSE:: To compare the efficacy and toxicities of irinotecan/platinum (IP) with etoposide/platinum (EP) in patients with previously untreated extensive-stage small cell lung cancer (E-SCLC). METHODS:: The PubMed database, the Cochrane Library, conference proceedings, databases of ongoing trials, and references of published trials and review articles were searched. Two reviewers independently assessed the quality of the trials and extracted data. The relative risk for overall response to treatment, hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios for the different types of toxicity were pooled by STATA package. RESULTS:: Six trials involving 1476 patients with previously untreated E-SCLC were ultimately analyzed. The intention-to-treatment analysis indicated that IP regimens could acquire more overall response than EP regimens (relative risk = 1.10, 95% confidence interval {lsqb;CI{rsqb;: 1.00-1.21, p = 0.043). The pooled HR showed that IP could prolong OS (HR = 0.81, 95% CI: 0.66-0.99, p = 0.044). Nevertheless, the pooled HR failed to show a favorable PFS in IP regimens (HR = 0.82, 95% CI: 0.64-1.06, p = 0.139). IP regimens led to less grade 3 to 4 anemia, neutropenia, and thrombocytopenia but more grade 3 to 4 vomiting and diarrhea than EP regimens. Treatment-related deaths were comparable between the two groups. CONCLUSION:: Although the PFS was similar from this meta-analysis, our results suggest that IP might have an advantage in overall response and OS compared with EP with less hematological toxicities. The IP regimens may be an alternative of EP regimens in the first-line treatment of E-SCLC. Copyright © 2010 by the International Association for the Study of Lung Cancer.

References Powered by Scopus

Assessing the quality of reports of randomized clinical trials: Is blinding necessary?

14739Citations
N/AReaders
Get full text

Cancer statistics, 2008

10417Citations
N/AReaders
Get full text

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

4060Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Small-cell lung cancer

947Citations
N/AReaders
Get full text

Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy

257Citations
N/AReaders
Get full text

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): A randomised phase 3 study

103Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jiang, J., Liang, X., Zhou, X., Huang, L., Huang, R., Chu, Z., & Zhan, Q. (2010). A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. Journal of Thoracic Oncology, 5(6), 867–873. https://doi.org/10.1097/JTO.0b013e3181d95c87

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

57%

Researcher 6

20%

Professor / Associate Prof. 5

17%

Lecturer / Post doc 2

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 23

74%

Pharmacology, Toxicology and Pharmaceut... 4

13%

Agricultural and Biological Sciences 2

6%

Arts and Humanities 2

6%

Save time finding and organizing research with Mendeley

Sign up for free